Key result
CPET-derived Peak VO2 remains critical for risk-stratifying and evaluating HF patients for LVAD or transplantation.
Why the study?
Shortness of breath and exercise limitation are often treated with improper focus because pathophysiology is poorly understood within each subspecialty.
Does cardiopulmonary exercise testing (CPET) provide prognostic value for risk stratification in patients with heart failure?
Does cardiopulmonary exercise testing (CPET) provide prognostic value for risk stratification in patients with heart failure?
Cardiopulmonary exercise testing, particularly the measurement of Peak VO2, is a vital tool for prognostic discrimination and risk stratification across the spectrum of heart failure.
Supports Peak VO2 for HF risk stratification and transplant evaluation; extends literature but leaves open prospective validation.
A robust literature, over the last years, supports the indication of cardiopulmonary exercise testing (CPET) in patients with cardiovascular diseases. Understanding exercise physiology is a crucial component of the critical evaluation of exercise intolerance. Shortness of breath and exercise limitation is often treated with an improper focus, partly because the pathophysiology is not well understood in the frame of the diagnostic spectrum of each subspecialty. A vital field and research area have been cardiopulmonary exercise test in heart failure with preserved/reduced ejection fraction, evaluation of heart failure patients as candidates for LVAD-Implantation, as well as for LVAD-Explantation and ultimately for heart transplantation. All the CPET variables provide synergistic prognostic discrimination. However, Peak VO2 serves as the most critical parameter for risk stratification and prediction of survival rate.
No takes yet. Share an insight, caveat, or question.
Sakellaropoulos et al. (2020) conducted a review in Heart failure. Cardiopulmonary exercise testing (CPET) was evaluated. Cardiopulmonary exercise testing, particularly Peak VO2, serves as a critical parameter for risk stratification, prediction of survival rate, and evaluation of heart failure patients for LVAD or transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: